Concerns regarding Roquefort Therapeutics and Ashington Innovations, Patricia Murray writes to the FCA
By Tom Winnifrith | Saturday 26 August 2023
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Patricia Murray of Liverpool has written to the FCA over both Ashington Innovations (ASHI) and Roquefort Therapeutics (ROQ). How a serious regulator can ignore what follows defies belief. Both companies are clearly utterly uninvestable. Ms Murray writes:
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.